Adicet Bio, INC Form 4 insider transactions

Lloyd Klickstein, Chief Medical Officer and a Director of Adicet Bio, Inc., received 18,300 shares of common stock on August 5, 2026.

RA Capital Management, L.P. has reported a transaction involving the exchange of common stock for a pre-funded warrant in Adicet Bio, Inc.

RA Capital Management, L.P. has acquired significant shares in Adicet Bio, Inc. through multiple transactions between February 18-20, 2026.

OrbiMed Advisors LLC and affiliated entities have reported significant transactions involving Adicet Bio, Inc. (ACET) common stock.

Adicet Bio's Chief Financial Officer, Brian Nicholas Harvey, was granted 43,361 stock options with an exercise price of $6.81.

Adicet Bio's President & CEO, Schor Chen, was granted 468,555 stock options with a $6.81 exercise price, vesting monthly over four years.

Adicet Bio's Chief Medical Officer, Julia D. Maltzman, was granted 72,555 stock options with an exercise price of $6.81, vesting monthly over four years.

Adicet Bio's Chief Technology Officer, Don Healey, was granted 43,361 stock options with a $6.81 exercise price, vesting monthly over four years.

Adicet Bio's Chief Scientific Officer, Blake Aftab, was granted 72,555 stock options with a $6.81 exercise price, vesting monthly over four years.

Adicet Bio's Chief Scientific Officer, Blake Aftab, reported the disposition of 535 common shares for tax withholding purposes following a recent reverse stock split.

Adicet Bio's Chief Technology Officer, Don Healey, reported a tax-related disposition of 535 common shares following a 1-for-16 reverse stock split.

Adicet Bio's President and CEO, Schor Chen, reported a transaction involving shares withheld by the company to cover tax obligations related to restricted stock unit vesting.

Adicet Bio's Chief Financial Officer, Brian Nicholas Harvey, reported a disposition of 546 common shares for tax withholding purposes following restricted stock unit vesting.

OrbiMed Advisors and its affiliated entities acquired 5 million shares of Adicet Bio common stock for $5 million in a registered direct offering.

Adicet Bio, Inc. Director Lloyd Klickstein was granted 5,900 Restricted Stock Units and options to purchase 26,400 shares of common stock as part of his compensation.

Adicet Bio, Inc. Director Jeffrey Chodakewitz was granted 5,900 Restricted Stock Units and options to purchase 26,400 shares of common stock on June 11, 2025, as part of his compensation.

Adicet Bio, Inc. Director Steve Dubin has reported the acquisition of 5,900 Restricted Stock Units and 26,400 stock options as part of his compensation, increasing his beneficial ownership in the company.

Adicet Bio, Inc. Director Katie Peng has reported the acquisition of 5,900 Restricted Stock Units (RSUs) and 26,400 stock options, aligning her interests with the company's long-term performance.

Adicet Bio, Inc. Director Andrew Sinclair was granted 5,900 Restricted Stock Units and options to purchase 26,400 shares of common stock on June 11, 2025, as part of his compensation.

Director Michael Grissinger acquired 70,200 stock options in Adicet Bio, Inc. on April 17, 2025, according to a Form 4 filing with the SEC.

Aftab Blake, Chief Scientific Officer of Adicet Bio, Inc., reports the acquisition of stock options.

Chen Schor, President & CEO of Adicet Bio, Inc., reports acquisition of stock options on January 31, 2025.

Don Healey, Chief Technology Officer of Adicet Bio, Inc., was granted stock options to purchase 275,000 shares of common stock on January 31, 2025.

Julia D. Maltzman, Chief Medical Officer of Adicet Bio, Inc., acquired 750,000 stock options on January 31, 2025, exercisable at $0.885 per share.

Brian Nicholas Harvey, CFO of Adicet Bio, Inc., reports the acquisition of stock options.

Chen Schor, President & CEO of Adicet Bio, reports adjustments to beneficial ownership of company stock due to tax withholding and corrections of previous overstatements.

Chief Technology Officer Don Healey of Adicet Bio, Inc. reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

Blake Aftab, Chief Scientific Officer of Adicet Bio, reports a transaction involving the withholding of shares to cover tax obligations related to vesting restricted stock units.

Adicet Bio's CFO, Brian Nicholas Harvey, disposed of shares to cover tax obligations related to vesting restricted stock units on January 24, 2025.

Andrew Sinclair, a director at Adicet Bio, reported adjustments to stock options due to the rescission of a prior repricing, reverting options to their original exercise prices.